Yescarta / FKC876 Approved in China for Adult Patients With ≥3L R/R DLBCL
Here is a brief preview of this blast: On Wednesday, June 23, Gilead announced (press release) that Yescarta (FKC876 / Yikeilen) has been approved by the Chinese NMPA for adult patients in ≥3L r/r DLBCL. Of note, Yescarta has become the first approved CAR-T in China. Below, Celltelligence provides insights on Yescarta’s Chinese regulatory history including which CAR-T could be approved next, while discussing the potential hurdles facing CAR-T reimbursement in China.